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Abstract 
 
Background—Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients 
with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac 
biomarkers in people with moderate-to-severe chronic kidney disease are unknown.  
Methods—UK HARP-III was a randomised double-blind trial which included 414 participants 
with an estimated glomerular filtration rate (GFR) 20-60 mL/min/1.73m2 who were randomly 
assigned to sacubitril/valsartan 97/103 mg twice daily versus irbesartan 300 mg once daily. The 
primary outcome was measured GFR (mGFR) at 12 months using analysis of covariance with 
adjustment for each individual's baseline mGFR. All analyses were by intention to treat. This 
trial is registered at ISRCTN11958993. 
Results—207 participants were assigned to sacubitril/valsartan and 207 to irbesartan. Baseline 
mGFR was 34.0 (0.8) and 34.7 (0.8) mL/min/1.73m² respectively. At 12 months there was no 
difference in measured GFR: 29.8 (SE 0.5) among those assigned sacubitril/valsartan versus 29.9 
(0.5) mL/min/1.73m2 among those assigned irbesartan; difference -0.1 (0.7) mL/min/1.73m2. 
Effects were similar in all pre-specified subgroups. There was also no significant difference in 
estimated GFR at 3, 6, 9 or 12 months and no clear difference in urinary albumin:creatinine ratio 
between treatment arms (study average difference -9%, 95% CI -18% to 1%). However, 
compared to irbesartan, allocation to sacubitril/valsartan reduced study average systolic and 
diastolic blood pressure by 5.4 (95% CI 3.4-7.4) and 2.1 (95% CI 1.0-3.3) mmHg, and levels of 
troponin I and N-terminal of pro-hormone brain natriuretic peptide (tertiary endpoints) by 16% 
(95% CI 8-23) and 18% (95% CI 11-25), respectively. The incidence of serious adverse events 
(29.5% vs 28.5%; rate ratio [RR] 1.07, 95% CI 0.75-1.53), non-serious adverse reactions (36.7% 
vs 28.0%; RR 1.35, 95% CI 0.96-1.90) and potassium ≥ 5.5 mmol/L (32% vs 24%; p=0.10) were 
not significantly different between randomized groups. 
Conclusions—Over 12 months, sacubitril/valsartan has similar effects on kidney function and 
albuminuria to irbesartan, but has the additional effect of lowering blood pressure and cardiac 
biomarkers in people with chronic kidney disease. 
Clinical Trial Registration—URL: www.isrctn.com Unique Identifier: ISRCTN11958993  
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Clinical Perspective 
 
What is new? 
• UK HARP-III has demonstrated that, in a wide range of people with proteinuric CKD, 
adding neprilysin inhibition to angiotensin II receptor blockade has no additional effect 
on kidney function or albuminuria compared to irbesartan.  
• The tolerability and safety profiles of the two treatments were not different, but as 
compared to irbesartan, sacubitril/valsartan further reduces both blood pressure and 
biomarkers of cardiovascular risk (troponin I and NT-proBNP) compared to irbesartan.  
 
What are the clinical implications? 
• UK HARP-III raises a hypothesis that sacubitril/valsartan could be an acceptable 
treatment to reduce cardiovascular risk in people with chronic kidney disease, a high-risk 
population with an unmet need.  
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Introduction 
Patients with chronic kidney disease (CKD) are at increased risk of both progression to end-stage 
renal disease (ESRD) and cardiovascular events, compared to patients with normal kidney 
function.1-3 Randomised controlled trials have shown that renin-angiotensin system (RAS) 
inhibitors slow the progression of diabetic and non-diabetic proteinuric CKD,4-7 and lowering 
low density lipoprotein cholesterol reduces the risk of atherosclerotic vascular events.8 However, 
despite such treatments, there remains a significant risk of progression to ESRD and 
cardiovascular events. In particular, patients with CKD are at increased risk of events related to 
structural heart disease (such as heart failure and arrhythmias), with many dying of 
cardiovascular disease before they reach ESRD.9 
 Natriuretic peptides have a range of potentially beneficial effects including natriuresis, 
diuresis, vasodilatation and inhibition of RAS.10, 11 Neprilysin (NEP; or neutral endopeptidase) is 
the key enzyme responsible for degrading natriuretic peptides and other vasoactive peptides such 
as angiotensin II, bradykinin, endothelin and substance P.10, 12 Although inhibition of neprilysin 
(NEPi) raises concentrations of circulating natriuretic peptides it also leads to reflex RAS 
activation and inhibits angiotensin II breakdown, counteracting any potentially beneficial effects, 
so NEPi must be combined with RAS inhibition. Combinations of NEPi and angiotensin 
converting enzyme inhibitors (ACEi) are associated with a high risk of angioedema (due to 
excessive inhibition of bradykinin degradation),13 so the chosen method of RAS inhibition for 
user with NEPi is an angiotensin receptor blockers (ARB). Sacubitril/valsartan, which combines 
an ARB (valsartan) with a NEPi (sacubitril), was the first angiotensin receptor-neprilysin 
inhibitor (ARNI) to be developed. 
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 The Prospective comparison of ARNI with ACEI to Determine Impact on Global 
Mortality and morbidity in Heart Failure trial (PARADIGM-HF) showed that sacubitril/valsartan 
reduced the risk of cardiovascular mortality among patients with heart failure with reduced 
ejection fraction when compared to ACEi (enalapril) (HR 0.80; 95% confidence interval 0.71-
0.89).14 Several trials in heart failure populations, including PARADIGM-HF, suggest that 
sacubitril/valsartan slows the decline in kidney function compared with RAS inhibition alone, 
but that it slightly increased albuminuria.15-17 Animal studies have shown that combining NEP 
and RAS inhibition can reduce proteinuria and histological evidence of kidney damage.18-21 The 
United Kingdom Heart and Renal Protection (UK HARP)-III trial aimed to compare the effects 
of sacubitril/valsartan versus irbesartan (a licenced ARB for diabetic nephropathy) on kidney 
function and other outcomes in people with CKD. 
 
Methods 
Trial design and participants 
The data, analytic methods, and study materials will be made available to other researchers for 
purposes of reproducing the results from the Richard Doll Centenary Archive according to the 
Nuffield Department for Population Health’s Data Sharing Policy.22 Details of the UK HARP-III 
trial objectives, design and methods have been reported previously.23 Ethical (Nottingham 
Research Ethics Committee 2 [13/EM/0434]) and regulatory approvals were obtained prior to the 
enrolment of any study participants. Participants aged 18 years and older were eligible to 
participate if they had chronic kidney disease with either (i) an estimated glomerular filtration 
rate (eGFR) of ≥45 and <60 mL/min/1.73m2 and a urine albumin:creatinine ratio (uACR) >20 
mg/mmol (177 mg/g); or (ii) an eGFR of ≥20 and <45 mL/min/1.73 m2 (regardless of uACR).  
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Potentially eligible participants attended a screening visit at which medical history and eligibility 
criteria were checked, written informed consent was obtained, and blood and urine samples were 
taken for local laboratory analysis. Any current RAS inhibitor was stopped and the participant 
entered the 4 to 7 week single-blind pre-randomisation run-in phase, during which they took one 
placebo sacubitril/valsartan tablet and one placebo irbesartan capsule daily. The aims of the run-
in phase were to (i) enable a ‘wash out’ of any ACEi prior to introduction of NEPi (to reduce the 
risk of angioedema), (ii) allow a comparison of the acute effects of the study treatments on eGFR 
and (iii) identify and exclude those less likely to adhere to study treatment and trial procedures 
prior to randomisation in order to maintain statistical sensitivity.24, 25  
Randomisation and masking 
At the end of the run-in period, GFR was measured and willing and eligible participants were 
randomized 1:1 to sacubitril/valsartan or irbesartan by an internet-based system with minimized 
randomisation (which helped ensure balance for categories of age, sex, systolic blood pressure, 
previous diabetes, eGFR and uACR).23 Treatment allocation was concealed, so investigators, 
clinicians and patients had no foreknowledge of the upcoming treatment allocation.26 A double-
dummy approach was used to ensure participants and study staff remained blind to treatment 
allocation: participants were issued two bottles of study treatments, one containing 
sacubitril/valsartan 97/103mg or placebo tablets and the other containing irbesartan 150mg or 
placebo capsules.27  
Procedures 
Following randomisation, participants were initially instructed to take one tablet and one capsule 
daily of study treatment (i.e. either sacubitril/valsartan 97/103mg or irbesartan 150mg); this was 
increased to sacubitril/valsartan 97/103mg twice daily or irbesartan 300mg once daily after two 
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weeks unless potassium or change in kidney function precluded a dose increase. Study visits 
were scheduled at 1, 3, 6, 9 and 12 months post-randomisation (and additional visits arranged 
where necessary to monitor participant safety). At each follow-up, study staff sought information 
on all serious adverse events and any non-serious adverse events considered with reasonable 
probability to be related to study treatment. Compliance with study treatments was assessed by 
self-report, and blood pressure and weight were measured at every visit. Blood and urine samples 
were collected at every study visit for local analysis of creatinine, potassium, liver function tests 
(bilirubin, liver transaminase and alkaline phosphatase) and uACR. Central laboratory assays of 
creatinine, uACR and cardiac biomarkers (troponin I and N-terminal pro-hormone of B-type 
natriuretic peptide, NT-proBNP) were conducted at randomisation, 6 and 12 months. 
Additionally, participants were advised not to take their morning dose of study treatment on the 
day of their 3 month visit so that creatinine, uACR, and trough blood levels of sacubitril, 
sacubitrilat (the primary metabolite of sacubitril) and valsartan could be collected. GFR was 
measured at or just prior to the 12 month visit, and paper results of all GFR measurements were 
sent to the coordinating centre for verification blind to treatment allocation. If participants were 
unwilling or no longer able to attend follow-up visits, information was obtained by telephone or 
from relatives or carers wherever possible. The original protocol specified that 360 participants 
would be followed for 6 months; prior to the completion of recruitment (and blind to any interim 
results) the Steering Committee decided to extend follow-up to 12 months (because of results 
from other trials suggesting the effect on kidney function may take at least 9 months to fully 
emerge) and to increase the sample size to at least 400 participants (to increase the statistical 
power). 
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Laboratory methods 
GFR was measured in the study centres using 51Cr-EDTA, 99mTc-DTPA or iohexol methods 
depending on local practice (with each centre using the same method used at baseline and 12 
months). Creatinine was assayed in the central laboratory on a Beckman Coulter AU680 analyser 
using a kinetic alkaline picrate method and calibrated using material traceable to isotope dilution 
mass spectrometry (using the National Institute of Standards and Technology Standard 
Reference Material 967); troponin I was measured by immunoassay on an Architect system and 
NT-proBNP by immunoassay on an Elecsys system. 
Statistical analysis 
The primary outcome was measured GFR (mGFR), Analysis of covariance (ANCOVA) was 
used to compare mean mGFR at 12 months between sacubitril/valsartan and irbesartan-allocated 
patients, with adjustment for each individual’s baseline mGFR.28 Assuming a between-person 
standard deviation (SD) in mGFR of 15 mL/min/1.73m2 and a correlation between an 
individual’s baseline and follow-up mGFR of 0.8, randomisation of 400 participants would 
provide at least 80% power (at P=0.05) to detect a difference in mGFR at the final follow-up 
(adjusted for baseline values) of 3 mL/min/1.73m2, even if 15% of participants discontinued 
allocated study treatment.  
 All analyses were performed according to the intention-to-treat principle among all 
randomized participants.29, 30 Comparisons of continuous outcomes were performed using 
ANCOVA adjusted for each participant’s baseline value, after appropriate transformation if 
required. Multiple imputation methods were used to account for missing data.31 Time-to-event 
analyses used log-rank methods to calculate event rate ratios (RRs), 95% confidence intervals 
(CIs) and associated two-sided p values. 29, 30 Pharmacokinetic analyses involved multiple linear 
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regression of each sacubitril/valsartan metabolite against a number of pre-specified baseline 
variables, adjusted for time since the last dose of sacubitril/valsartan. The primary 
pharmacokinetic analysis restricted the dataset to those participants assigned sacubitril/valsartan 
who had last taken the drug 10-16 hours prior to the sample being collected. Further details 
(including secondary and tertiary outcomes) are available in the pre-specified data analysis 
plan.23 Analyses were done using SAS version 9.3 (SAS Institute, Cary) and R version 3.3.3 
(www.R-Project.org). 
Sources of Funding 
The UK HARP-III trial was designed, conducted, and analysed by the MRC Population Health 
Research Unit, which is part of the Clinical Trial Service Unit and Epidemiological Studies Unit. 
The University of Oxford was the independent regulatory sponsor for the study. The study was 
funded by a grant to the University of Oxford from Novartis (manufacturers of 
sacubitril/valsartan). The funder had no involvement in the study conduct, analysis or the 
decision to submit for publication. All authors accept full responsibility for the content of this 
paper. The first author had full access to all the data in the study and take responsibility for its 
integrity and the data analysis. 
Clinical Trial Registration 
The trial is registered at ISRCTN11958993 (www.isrctn.com) 
 
Results 
Between 1st November 2014 and 31st January 2016, 620 participants attended screening visits 
and 566 (91%) entered the pre-randomisation run-in (Figure 1). 414 participants were 
randomized: 207 to sacubitril/valsartan and 207 to irbesartan. Mean age was 62.8 years (SD 
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13.7), 298 (72%) were male and mean blood pressure was 146/81 mmHg (Table 1). Mean eGFR 
at baseline was 35.5 (10.9) mL/min/1.73m² and median uACR was 54 (interquartile range 11-
153) mg/mmol (Table 1).  
 By 12 months, similar proportions of participants in each arm had stopped study 
treatment (33 [16%] of those assigned sacubitril/valsartan and 34 [16%] of those assigned 
irbesartan) and the reasons for stopping full dose study treatment were similar. There was no 
excess of discontinuations due to serious adverse events, non-serious adverse reactions or other 
reasons in thos allocated sacubitril/valsartan (Supplementary Table 1). 
 At 12 months, the mean (SE) mGFR was 29.8 (0.5) mL/min/1.73m² among those 
assigned sacubitril/valsartan group compared with 29.9 (0.5) mL/min/1.73m² among those 
assigned irbesartan, a non-significant difference of 0.1 (0.7) mL/min/1.73m² (P=0.86; Table 2). 
Neither a pre-specified complete case analysis (i.e. without imputation: difference -0.4 (0.7) 
mL/min/1.73m²) nor an “on treatment” analysis (difference -0.5 (0.7) mL/min/1.73m²) materially 
affected this finding. There was no evidence that the difference between sacubitril/valsartan and 
irbesartan in effect on mGFR differed by age (χ12=0.45; p=0.50), sex (χ12=0.70; p=0.4), by 
baseline mGFR (χ12=0.42; p=0.52), baseline uACR (χ12=0.76; p=0.38), cause of kidney disease 
(χ62=2.24; p=0.90) or any other pre-specified baseline characteristic (Supplementary Figure 1).  
 As compared to irbesartan, allocation to sacubitril/valsartan was not associated with any 
significant effect on eGFR at any time point (Figure 2). The rate of change in eGFR did not 
differ significantly between arms, whether measured from randomisation to 12 months, from 
randomisation to 3 months or from 3 to 12 months (Supplementary Table 2).  
 Allocation to sacubitril/valsartan produced a non-significant 9% (-18 to 1%; p=0.08) 
reduction in study-average uACR (Table 3) and was associated with a reduction in blood 
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pressure compared with irbesartan. Overall, mean systolic blood pressure was 5.4 (95% CI -7.4 
to -3.4) mmHg lower, and mean diastolic blood pressure was 2.1 (95% CI -3.3 to -1.0) mmHg 
lower among those allocated to sacubitril/valsartan (Table 3). Exploratory analyses did not show 
any differences in the intensity of non-study anti-hypertensive agents between the treatment arms 
during follow-up. 
 Allocation to sacubitril/valsartan was associated with significant reductions in levels of 
cardiac biomarkers compared with irbesartan. Study average NT-proBNP concentrations were 
18% (-25 to -11%) lower and troponin I levels were 16% (-23% to -8%) lower among 
participants assigned sacubitril/valsartan (Table 3). 
 Using data from 87 participants who had taken their last dose of sacubitril/valsartan 10-
16 hours previously, no significant determinants of sacubitril or valsartan concentration were 
identified (Supplementary Table 3). However, kidney function was a major determinant of 
sacubitrilat concentration, with each 10 mL/min lower mGFR being associated with a 1485 (572-
2397) ng/mL higher sacubitrilat concentration (Supplementary Table 3).  
 Allocation to sacubitril/valsartan had no significant effect on fatal serious adverse events 
(1 [0.5%] vs 1 [0.5%]) or on any non-fatal serious adverse events (61 [29.5%] vs 59 [28.5%]; RR 
1.07 [0.75-1.53]; p=0.70) (Supplementary Table 4). One case of angioedema occurred in a 
participant allocated sacubitril/valsartan, but they did not attend hospital or require any specific 
treatment. There was no difference overall in the number of non-serious adverse reactions (76 
[36.7%] vs 58 [28.0%]; RR 1.35 [0.96-1.90]; p=0.08) (Supplementary Table 4). Allocation to 
sacubitril/valsartan was associated with higher rates of non-serious hypotension (17 [8.2%] vs 7 
[3.4%]; RR 2.36 [1.06-5.26]; p=0.04).  There was no difference between treatments in the 
number of participants experiencing hyperkalaemia (66 [32%] vs 50 [24%]; p=0.10) or in the 
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proportion experiencing a significant decline in eGFR (defined as 25% or greater reduction; 71 
[34%] vs 67 [32%]; p=0.75) (Table 4). There were no cases of significant liver injury. 
 
Discussion 
The UK HARP-III trial has shown that, compared with irbesartan, 12 months of treatment with 
sacubitril/valsartan did not significantly affect kidney function in people with CKD. 
Sacubitril/valsartan had no additional effect on albuminuria compared to irbesartan and was as 
well-tolerated, with no major safety concerns identified. Sacubitril/valsartan was also found to 
reduce blood pressure and biomarkers of cardiovascular risk (troponin I and NT-proBNP) 
compared to irbesartan. 
 The kidney function results from UK HARP-III do not confirm findings from the 
analyses of kidney disease progression outcomes from other NEPi trials among patients with 
heart failure. In a trial among patients with heart failure with preserved ejection fraction 
(HFpEF), kidney function declined more slowly with sacubitril/valsartan compared with 
valsartan.15 In the large PARADIGM-HF trial, a marginally slower decline in eGFR was also 
observed with sacubitril/valsartan compared with enalapril (-1.3 [-1.2 to -1.4]  versus -1.8 [-1.8 
to -1.7] mL/min/1.73m2 per year; p<0.0001).16 The lack of any additional effect of 
sacubitril/valsartan on kidney function in UK HARP-III may reflect differing determinants of 
kidney disease progression in a proteinuric CKD population compared to heart failure 
populations. If cardiac function is a more important determinant of kidney function in a heart 
failure population than in proteinuric CKD, then a treatment which improves cardiac function, 
like sacubitril/valsartan, might be more likely to affect kidney function in a heart failure 
population. 
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 Studies using animal models of established kidney disease have found that combinations 
of NEP and RAS inhibition are not associated with significant differences in GFR compared with 
isolated RAS inhibition.18, 19, 21, 32 However, histology results from these animals demonstrated 
that combined NEP/RAS inhibition was associated with greater reductions in histological 
markers of CKD progression (glomerulosclerosis and tubulointerstitial fibrosis), compared with 
isolated RAS inhibition.12, 18-20 It should be noted that the largest decline in eGFR was observed 
during the first month, likely attributable to the known glomerular haemodynamic effects of RAS 
inhibition. In the remaining 11 months of observation, eGFR decline was slow in both groups, 
implying that a longer observation period may have been necessary to observe the full effect on 
kidney function. 
 Allocation to sacubitril/valsartan did not increase albuminuria, by contrast with trials 
among patients with heart failure among whom sacubitril/valsartan causes statistically significant 
(but clinically modest) increases in albuminuria (from a much lower baseline).15 If similar 
increases in albuminuria had developed in people with proteinuric CKD, this would have been of 
concern since albuminuria is associated with increased risk of progression to ESRD (although 
whether this association is directly causal remains uncertain).33-35 Nonetheless, the lack of effect 
on albuminuria despite the observed blood pressure difference raises the possibility that the 
effect on systemic blood pressure does not lead to a reduction in intraglomerular pressure. 
 Sacubitril/valsartan lowered blood pressure compared with irbesartan. Similar additional 
reductions in blood pressure compared with RAS inhibition have been shown in populations with 
heart failure or hypertension.14, 36-39 These differences were observed in the context of a median 
of one other anti-hypertensive medication being used in addition to study treatment in both 
groups. It remains uncertain whether lowering blood pressure reduces the rate of progression of 
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kidney disease,40, 41 but there is good evidence that it reduces the risk of cardiovascular events.41 
Patients with CKD are at increased risk of cardiovascular events;42 indeed, most patients with 
CKD are at higher risk of cardiovascular mortality than progression to end-stage kidney disease 
(i.e. dialysis or transplantation).9 As kidney function declines, the nature of cardiovascular 
disease changes from a typical atherosclerotic phenotype to one of structural heart disease which 
becomes increasingly prevalent such that 80% of patients starting dialysis have evidence of it.43, 
44 The finding   that NTpro-BNP (an indicator of cardiac wall stress and not a substrate of 
neprilysin) and troponin levels (a marker of cardiomyocyte necrosis) were both lower among 
participants assigned sacubitril/valsartan compared with irbesartan  has also been observed 
among patients with heart failure.39, 45, 46 Recent animal data also demonstrated that 
sacubitril/valsartan attenuates cardiac hypertrophy and fibrosis in an animal model of CKD.47 
These findings raise the hypothesis that sacubitril/valsartan may have cardiovascular benefits 
among patients with advanced CKD and provides a rationale for a clinical outcome trial.  
 Sacubitril/valsartan was generally well-tolerated and no major hazards were observed; 
although there were numerically more non-serious adverse reactions in the sacubitril/valsartan 
group this difference was not statistically significant. These randomised comparisons follow a 
placebo run-in during which 152/566 (26%) of participants withdrew, mostly for non-medical 
reasons.23 Compared to those allocated to irbesartan, there were more reports of symptoms of 
hypotension among participants allocated sacubitril/valsartan, which is expected given its larger 
blood pressure lowering effect. Because kidney function is a major determinant of sacubitrilat 
concentration, it is possible that higher concentrations of sacubitrilat in this population 
contributed to this excess in hypotension. Both treatments had similar effects on the incidence of 
hyperkalaemia and no cases of significant liver injury were observed despite high blood 
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concentrations of sacubitrilat resulting from reduced renal excretion. One participant allocated 
sacubitril/valsartan developed angioedema but did not require medical intervention and it 
resolved spontaneously.  
 Study limitations include the short duration of follow-up and the sample size which was 
not sufficiently large to test the effect of sacubitril/valsartan on clinical outcomes. The choice of 
comparator (irbesartan) might also have an effect on the interpretation of the results as it has a 
different pharmacological profile to valsartan and may provide more intense angiotensin receptor 
blockade.48 This would suggest the additional BP reduction and effects on cardiac biomarkers are 
an underestimate of the effect of neprilysin inhibition. 
 In conclusion, over 12 months in people with chronic kidney disease, the combination of 
sacubitril and valsartan is well-tolerated and has similar effects on kidney function and 
albuminuria to irbesartan, but has additional blood pressure and cardiac biomarker lowering 
effects. 
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Table 1. Baseline characteristics by randomised treatment allocation 
 
 
Sacubitril/valsartan  
(n=207) 
Irbesartan  
(n=207) 
   
Age at randomisation (years) 62.0 (14.1) 63.6 (13.4) 
<50 37 (18%) 36 (17%) 
≥50 to <70 97 (47%) 99 (48%) 
≥70 73 (35%) 72 (35%) 
Sex   
Male 148 (71%) 150 (72%) 
Female 59 (29%) 57 (28%) 
Ethnicity   
White 186 (90%) 191 (92%) 
Black 3 (1%) 4 (2%) 
South Asian 11 (5%) 7 (3%) 
Other 7 (3%) 5 (2%) 
Self-reported prior disease   
Coronary heart disease 21 (10%) 33 (16%) 
Cerebrovascular disease 16 (8%) 15 (7%) 
Peripheral vascular disease 22 (11%) 22 (11%) 
Heart failure 8 (4%) 7 (3%) 
Diabetes mellitus 81 (39%) 83 (40%) 
Systolic blood pressure at randomisation (mmHg) 146 (16) 146 (16) 
<140 76 (37%) 85 (41%) 
≥140 to <160 93 (45%) 84 (41%) 
≥160 38 (18%) 38 (18%) 
Diastolic blood pressure at randomisation (mmHg) 81 (11) 80 (11) 
<80 96 (46%) 105 (51%) 
≥80 to <90 68 (33%) 58 (28%) 
≥90 43 (21%) 44 (21%) 
Body mass index (kg/m²) 30 (6) 31 (6) 
<25 35 (17%) 33 (16%) 
≥25 to <30 74 (36%) 73 (35%) 
≥30 95 (46%) 100 (48%) 
Not available 3 1 
Medication   
Antiplatelet therapy 64 (31%) 75 (36%) 
Oral anticoagulant 13 (6%) 15 (7%) 
Diuretic 79 (38%) 85 (41%) 
Calcium channel blocker 104 (50%) 103 (50%) 
Beta blocker 50 (24%) 62 (30%) 
Alpha blocker 58 (28%) 55 (27%) 
LDL-lowering agent 126 (61%) 137 (66%) 
Use of RAS blockade at screening visit   
Yes 173 (84%) 166 (80%) 
No 34 (16%) 41 (20%) 
CKD-EPI estimated glomerular filtration rate at randomisation 
(mL/min/1.73m²)   
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Sacubitril/valsartan  
(n=207) 
Irbesartan  
(n=207) 
Mean (SD) 35.4 (11.0) 35.5 (11.0) 
<30 79 (38%) 77 (37%) 
≥30 to <45 86 (42%) 91 (44%) 
≥45 41 (20%) 39 (19%) 
Not available 1 0 
Urine albumin:creatinine ratio at randomisation (mg/mmol)   
Geometric mean (approx SE) 34 (5) 34 (5) 
Median (IQR) 52 (11-162) 56 (11-146) 
<3 30 (14%) 28 (14%) 
≥3 to <30 43 (21%) 45 (22%) 
≥30 134 (65%) 134 (65%) 
Cause of kidney disease   
Glomerular disease 60 (29%) 51 (25%) 
Tubulointerstitial disease* 18 (9%) 32 (15%) 
Diabetic kidney disease† 36 (17%) 47 (23%) 
Hypertensive/renovascular disease† 18 (9%) 24 (12%) 
Other systemic diseases affecting the kidneys† 1 (0%) 2 (1%) 
Familial/hereditary nephropathies 30 (14%) 13 (6%) 
Other known causes‡ 5 (2%) 4 (2%) 
Unknown‡ 39 (19%) 34 (16%) 
24 hour urinary sodium excretion during run-in (mg/24 hours)   
Geometric mean (approx SE) 2245 (183) 2585 (187) 
Median (IQR) 2484 (1794-3795) 2875 (1932-4232) 
Not available 100 110 
Values are n (%), mean (SD), geometric mean (approx SE) or median (IQR). RAS=Renin–angiotensin 
system. CKD-EPI=Chronic kidney disease Epidemiology Collaboration. *Includes obstructive renal 
diseases. †All considered 'Systemic diseases affecting the kidney' by the ERA-EDTA registry. ‡All 
considered 'Miscellaneous renal disorders' by the ERA-EDTA registry. 
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Table 2. Effect of allocation to sacubitril/valsartan versus irbesartan on measured glomerular filtration 
rate at 12 months 
 
Follow-up visit 
Mean mGFR (SE) (mL/min/1.73m²) Difference in means 
(SE)* p value Sacubitril/valsartan (n=207) Irbesartan (n=207) 
Randomisation 34.0 (0.8) 34.7 (0.8)   
12 months 29.8 (0.5) 29.9 (0.5) -0.1 (0.7) 0.86 
mGFR=measured glomerular filtration rate. Where the difference between mGFR and central eGFR at the 
corresponding time point was more extreme than the 1st or 99th centile of the distribution of differences, 
the value of mGFR was set to missing. 10 missing mGFR values at randomisation had eGFR values at 
randomisation imputed and 41 missing mGFR values at 12 months were imputed with the use of multiple 
imputation. For the 2 patients who commenced chronic dialysis during the study, a value of 0 was 
imputed for their 12 month mGFR. *Values are absolute differences in arithmetic means (SE). The 12 
month estimates and p values were derived from analysis of covariance with adjustment for the 
randomisation value. 
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Table 3. Effect of allocation to sacubitril/valsartan versus irbesartan on urinary albumin:creatinine ratio, systolic and diastolic blood pressure and 
cardiac biomarkers  
 
Follow-up visit 
Mean (SE)* Difference in means 
(95% CI)† p value Sacubitril/valsartan (n=207) Irbesartan (n=207) 
Urinary albumin:creatinine ratio (mg/mmol)     
Randomisation 34.1 (4.6) 33.9 (4.5)   
3 months 17.0 (1.0) 17.8 (1.0) -4% (-19 to 12%)  
6 months 15.6 (1.0) 18.4 (1.1) -15% (-28 to 0%)  
12 months 16.4 (1.2) 17.6 (1.3) -6% (-23 to 14%)  
Study average 16.3 (0.6) 17.9 (0.7) -9% (-18 to 1%) 0.08 
Systolic blood pressure (mmHg)     
Randomisation 146 (1.1) 146 (1.1)   
1 month 129 (1.1) 132 (1.1) -3.5 (-6.5 to -0.6)  
3 months 129 (1.1) 137 (1.1) -7.3 (-10.3 to -4.3)  
6 months 128 (1.1) 135 (1.1) -6.9 (-10.0 to -3.7)  
9 months 130 (1.2) 134 (1.2) -4.0 (-7.3 to -0.8)  
12 months 128 (2.5) 133 (2.2) -4.4 (-10.9 to 2.1)  
Study average 129 (0.8) 134 (0.7) -5.4 (-7.4 to -3.4) <0.001 
Diastolic blood pressure (mmHg)     
Randomisation 81 (0.8) 80 (0.8)   
1 month 73 (0.6) 74 (0.6) -0.8 (-2.5 to 0.9)  
3 months 73 (0.6) 76 (0.6) -2.6 (-4.3 to -0.9)  
6 months 72 (0.6) 75 (0.6) -2.5 (-4.2 to -0.8)  
9 months 73 (0.6) 74 (0.6) -1.8 (-3.6 to -0.1)  
12 months 72 (1.6) 75 (1.3) -2.2 (-6.2 to 1.9)  
Study average 73 (0.5) 75 (0.4) -2.1 (-3.3 to -1.0) <0.001 
N-Terminal Pro B-type Natriuretic Peptide (ng/L)     
Randomisation 254.5 (22) 250.9 (22)   
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Follow-up visit 
Mean (SE)* Difference in means 
(95% CI)† p value Sacubitril/valsartan (n=207) Irbesartan (n=207) 
6 months 175.6 (7.2) 219.7 (8.9) -20% (-29 to -11%)  
12 months 210.2 (11) 247.5 (12) -15% (-26 to -2%)  
Study average 188.7 (6.0) 230.4 (7.3) -18% (-25 to -11%) <0.001 
Troponin I (ng/L)     
Randomisation 7.3 (0.5) 7.5 (0.5)   
6 months 5.4 (0.2) 6.6 (0.2) -19% (-27 to -10%)  
12 months 6.3 (0.4) 7.1 (0.4) -11% (-24 to 4%)  
Study average 5.7 (0.2) 6.8 (0.2) -16% (-23 to -8%) <0.001 
Any missing data were imputed with the use of multiple imputation. *Geometric means (approx SE) are presented for urinary albumin:creatinine 
ratio and cardiac biomarkers, and arithmetic means (SE) are presented for blood pressure. †Values are percentage changes in geometric means 
(95% CI) for urinary albumin:creatinine ratio and cardiac biomarkers, and absolute differences in arithmetic means (95% CI) for blood pressure. 
The estimates and p values at each follow-up visit were derived from analysis of covariance with adjustment for the randomisation value. 
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Table 4. Effect of allocation to sacubitril/valsartan versus irbesartan on biochemical safety data 
 
Outcome 
Sacubitril/valsartan 
(n=207) 
Irbesartan 
(n=207) p-value 
Potassium (mmol/L)    
≥5.5 to <6.0 44 (21%) 38 (18%)  
≥6.0 to <6.5 20 (10%) 7 (3%)  
≥6.5 2 (1%) 5 (2%)  
Total: Any potassium ≥5.5 mmol/L 66 (32%) 50 (24%) 0.10 
Estimated glomerular filtration rate    
≥25% reduction in CKD-EPI eGFR* 71 (34%) 67 (32%) 0.75 
CKD-EPI=Chronic kidney disease Epidemiology Collaboration. eGFR=estimated glomerular filtration 
rate. Based on local laboratory measurements. *compared to eGFR at randomisation visit. 
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Figure Legends 
 
Figure 1. Flow of participants 
* Participants could report more than one reason 
† The duration of the trial was increased from 6 to 12 months and 9 participants did not consent 
to this extension so completed follow-up at 6 months. 
 
Figure 2. Effect of allocation to sacubitril/valsartan versus irbesartan on estimated 
glomerular filtration rate  
Creatinine measured in central laboratory except for 1 and 9 month visits when creatinine was 
measured in local laboratory. Error bars presented are 95% confidence intervals. 
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Abstract 
 
Background—Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients 
with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac 
biomarkers in people with moderate-to-severe chronic kidney disease are unknown.  
Methods—UK HARP-III was a randomised double-blind trial which included 414 participants 
with an estimated glomerular filtration rate (GFR) 20-60 mL/min/1.73m2 who were randomly 
assigned to sacubitril/valsartan 97/103 mg twice daily versus irbesartan 300 mg once daily. The 
primary outcome was measured GFR (mGFR) at 12 months using analysis of covariance with 
adjustment for each individual's baseline mGFR. All analyses were by intention to treat. This 
trial is registered at ISRCTN11958993. 
Results—207 participants were assigned to sacubitril/valsartan and 207 to irbesartan. Baseline 
mGFR was 34.0 (0.8) and 34.7 (0.8) mL/min/1.73m² respectively. At 12 months there was no 
difference in measured GFR: 29.8 (SE 0.5) among those assigned sacubitril/valsartan versus 29.9 
(0.5) mL/min/1.73m2 among those assigned irbesartan; difference -0.1 (0.7) mL/min/1.73m2. 
Effects were similar in all pre-specified subgroups. There was also no significant difference in 
estimated GFR at 3, 6, 9 or 12 months and no clear difference in urinary albumin:creatinine ratio 
between treatment arms (study average difference -9%, 95% CI -18% to 1%). However, 
compared to irbesartan, allocation to sacubitril/valsartan reduced study average systolic and 
diastolic blood pressure by 5.4 (95% CI 3.4-7.4) and 2.1 (95% CI 1.0-3.3) mmHg, and levels of 
troponin I and N-terminal of pro-hormone brain natriuretic peptide (tertiary endpoints) by 16% 
(95% CI 8-23) and 18% (95% CI 11-25), respectively. The incidence of serious adverse events 
(29.5% vs 28.5%; rate ratio [RR] 1.07, 95% CI 0.75-1.53), non-serious adverse reactions (36.7% 
vs 28.0%; RR 1.35, 95% CI 0.96-1.90) and potassium ≥ 5.5 mmol/L (32% vs 24%; p=0.10) were 
not significantly different between randomized groups. 
Conclusions—Over 12 months, sacubitril/valsartan has similar effects on kidney function and 
albuminuria to irbesartan, but has the additional effect of lowering blood pressure and cardiac 
biomarkers in people with chronic kidney disease. 
Clinical Trial Registration—URL: www.isrctn.com Unique Identifier: ISRCTN11958993  
 
Key Words: Chronic kidney disease; neprilysin inhibition; renin-angiotensin system 
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Clinical Perspective 
 
What is new? 
• UK HARP-III has demonstrated that, in a wide range of people with proteinuric CKD, 
adding neprilysin inhibition to angiotensin II receptor blockade has no additional effect 
on kidney function or albuminuria compared to irbesartan.  
• The tolerability and safety profiles of the two treatments were not different, but as 
compared to irbesartan, sacubitril/valsartan further reduces both blood pressure and 
biomarkers of cardiovascular risk (troponin I and NT-proBNP) compared to irbesartan.  
 
What are the clinical implications? 
• UK HARP-III raises a hypothesis that sacubitril/valsartan could be an acceptable 
treatment to reduce cardiovascular risk in people with chronic kidney disease, a high-risk 
population with an unmet need.  
10.1161/CIRCULATIONAHA.118.034818 
4 
Introduction 
Patients with chronic kidney disease (CKD) are at increased risk of both progression to end-stage 
renal disease (ESRD) and cardiovascular events, compared to patients with normal kidney 
function.1-3 Randomised controlled trials have shown that renin-angiotensin system (RAS) 
inhibitors slow the progression of diabetic and non-diabetic proteinuric CKD,4-7 and lowering 
low density lipoprotein cholesterol reduces the risk of atherosclerotic vascular events.8 However, 
despite such treatments, there remains a significant risk of progression to ESRD and 
cardiovascular events. In particular, patients with CKD are at increased risk of events related to 
structural heart disease (such as heart failure and arrhythmias), with many dying of 
cardiovascular disease before they reach ESRD.9 
 Natriuretic peptides have a range of potentially beneficial effects including natriuresis, 
diuresis, vasodilatation and inhibition of RAS.10, 11 Neprilysin (NEP; or neutral endopeptidase) is 
the key enzyme responsible for degrading natriuretic peptides and other vasoactive peptides such 
as angiotensin II, bradykinin, endothelin and substance P.10, 12 Although inhibition of neprilysin 
(NEPi) raises concentrations of circulating natriuretic peptides it also leads to reflex RAS 
activation and inhibits angiotensin II breakdown, counteracting any potentially beneficial effects, 
so NEPi must be combined with RAS inhibition. Combinations of NEPi and angiotensin 
converting enzyme inhibitors (ACEi) are associated with a high risk of angioedema (due to 
excessive inhibition of bradykinin degradation),13 so the chosen method of RAS inhibition for 
user with NEPi is an angiotensin receptor blockers (ARB). Sacubitril/valsartan, which combines 
an ARB (valsartan) with a NEPi (sacubitril), was the first angiotensin receptor-neprilysin 
inhibitor (ARNI) to be developed. 
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 The Prospective comparison of ARNI with ACEI to Determine Impact on Global 
Mortality and morbidity in Heart Failure trial (PARADIGM-HF) showed that sacubitril/valsartan 
reduced the risk of cardiovascular mortality among patients with heart failure with reduced 
ejection fraction when compared to ACEi (enalapril) (HR 0.80; 95% confidence interval 0.71-
0.89).14 Several trials in heart failure populations, including PARADIGM-HF, suggest that 
sacubitril/valsartan slows the decline in kidney function compared with RAS inhibition alone, 
but that it slightly increased albuminuria.15-17 Animal studies have shown that combining NEP 
and RAS inhibition can reduce proteinuria and histological evidence of kidney damage.18-21 The 
United Kingdom Heart and Renal Protection (UK HARP)-III trial aimed to compare the effects 
of sacubitril/valsartan versus irbesartan (a licenced ARB for diabetic nephropathy) on kidney 
function and other outcomes in people with CKD. 
 
Methods 
Trial design and participants 
The data, analytic methods, and study materials will be made available to other researchers for 
purposes of reproducing the results from the Richard Doll Centenary Archive according to the 
Nuffield Department for Population Health’s Data Sharing Policy.22 Details of the UK HARP-III 
trial objectives, design and methods have been reported previously.23 Ethical (Nottingham 
Research Ethics Committee 2 [13/EM/0434]) and regulatory approvals were obtained prior to the 
enrolment of any study participants. Participants aged 18 years and older were eligible to 
participate if they had chronic kidney disease with either (i) an estimated glomerular filtration 
rate (eGFR) of ≥45 and <60 mL/min/1.73m2 and a urine albumin:creatinine ratio (uACR) >20 
mg/mmol (177 mg/g); or (ii) an eGFR of ≥20 and <45 mL/min/1.73 m2 (regardless of uACR).  
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Potentially eligible participants attended a screening visit at which medical history and eligibility 
criteria were checked, written informed consent was obtained, and blood and urine samples were 
taken for local laboratory analysis. Any current RAS inhibitor was stopped and the participant 
entered the 4 to 7 week single-blind pre-randomisation run-in phase, during which they took one 
placebo sacubitril/valsartan tablet and one placebo irbesartan capsule daily. The aims of the run-
in phase were to (i) enable a ‘wash out’ of any ACEi prior to introduction of NEPi (to reduce the 
risk of angioedema), (ii) allow a comparison of the acute effects of the study treatments on eGFR 
and (iii) identify and exclude those less likely to adhere to study treatment and trial procedures 
prior to randomisation in order to maintain statistical sensitivity.24, 25  
Randomisation and masking 
At the end of the run-in period, GFR was measured and willing and eligible participants were 
randomized 1:1 to sacubitril/valsartan or irbesartan by an internet-based system with minimized 
randomisation (which helped ensure balance for categories of age, sex, systolic blood pressure, 
previous diabetes, eGFR and uACR).23 Treatment allocation was concealed, so investigators, 
clinicians and patients had no foreknowledge of the upcoming treatment allocation.26 A double-
dummy approach was used to ensure participants and study staff remained blind to treatment 
allocation: participants were issued two bottles of study treatments, one containing 
sacubitril/valsartan 97/103mg or placebo tablets and the other containing irbesartan 150mg or 
placebo capsules.27  
Procedures 
Following randomisation, participants were initially instructed to take one tablet and one capsule 
daily of study treatment (i.e. either sacubitril/valsartan 97/103mg or irbesartan 150mg); this was 
increased to sacubitril/valsartan 97/103mg twice daily or irbesartan 300mg once daily after two 
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weeks unless potassium or change in kidney function precluded a dose increase. Study visits 
were scheduled at 1, 3, 6, 9 and 12 months post-randomisation (and additional visits arranged 
where necessary to monitor participant safety). At each follow-up, study staff sought information 
on all serious adverse events and any non-serious adverse events considered with reasonable 
probability to be related to study treatment. Compliance with study treatments was assessed by 
self-report, and blood pressure and weight were measured at every visit. Blood and urine samples 
were collected at every study visit for local analysis of creatinine, potassium, liver function tests 
(bilirubin, liver transaminase and alkaline phosphatase) and uACR. Central laboratory assays of 
creatinine, uACR and cardiac biomarkers (troponin I and N-terminal pro-hormone of B-type 
natriuretic peptide, NT-proBNP) were conducted at randomisation, 6 and 12 months. 
Additionally, participants were advised not to take their morning dose of study treatment on the 
day of their 3 month visit so that creatinine, uACR, and trough blood levels of sacubitril, 
sacubitrilat (the primary metabolite of sacubitril) and valsartan could be collected. GFR was 
measured at or just prior to the 12 month visit, and paper results of all GFR measurements were 
sent to the coordinating centre for verification blind to treatment allocation. If participants were 
unwilling or no longer able to attend follow-up visits, information was obtained by telephone or 
from relatives or carers wherever possible. The original protocol specified that 360 participants 
would be followed for 6 months; prior to the completion of recruitment (and blind to any interim 
results) the Steering Committee decided to extend follow-up to 12 months (because of results 
from other trials suggesting the effect on kidney function may take at least 9 months to fully 
emerge) and to increase the sample size to at least 400 participants (to increase the statistical 
power). 
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Laboratory methods 
GFR was measured in the study centres using 51Cr-EDTA, 99mTc-DTPA or iohexol methods 
depending on local practice (with each centre using the same method used at baseline and 12 
months). Creatinine was assayed in the central laboratory on a Beckman Coulter AU680 analyser 
using a kinetic alkaline picrate method and calibrated using material traceable to isotope dilution 
mass spectrometry (using the National Institute of Standards and Technology Standard 
Reference Material 967); troponin I was measured by immunoassay on an Architect system and 
NT-proBNP by immunoassay on an Elecsys system. 
Statistical analysis 
The primary outcome was measured GFR (mGFR), Analysis of covariance (ANCOVA) was 
used to compare mean mGFR at 12 months between sacubitril/valsartan and irbesartan-allocated 
patients, with adjustment for each individual’s baseline mGFR.28 Assuming a between-person 
standard deviation (SD) in mGFR of 15 mL/min/1.73m2 and a correlation between an 
individual’s baseline and follow-up mGFR of 0.8, randomisation of 400 participants would 
provide at least 80% power (at P=0.05) to detect a difference in mGFR at the final follow-up 
(adjusted for baseline values) of 3 mL/min/1.73m2, even if 15% of participants discontinued 
allocated study treatment.  
 All analyses were performed according to the intention-to-treat principle among all 
randomized participants.29, 30 Comparisons of continuous outcomes were performed using 
ANCOVA adjusted for each participant’s baseline value, after appropriate transformation if 
required. Multiple imputation methods were used to account for missing data.31 Time-to-event 
analyses used log-rank methods to calculate event rate ratios (RRs), 95% confidence intervals 
(CIs) and associated two-sided p values. 29, 30 Pharmacokinetic analyses involved multiple linear 
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regression of each sacubitril/valsartan metabolite against a number of pre-specified baseline 
variables, adjusted for time since the last dose of sacubitril/valsartan. The primary 
pharmacokinetic analysis restricted the dataset to those participants assigned sacubitril/valsartan 
who had last taken the drug 10-16 hours prior to the sample being collected. Further details 
(including secondary and tertiary outcomes) are available in the pre-specified data analysis 
plan.23 Analyses were done using SAS version 9.3 (SAS Institute, Cary) and R version 3.3.3 
(www.R-Project.org). 
Sources of Funding 
The UK HARP-III trial was designed, conducted, and analysed by the MRC Population Health 
Research Unit, which is part of the Clinical Trial Service Unit and Epidemiological Studies Unit. 
The University of Oxford was the independent regulatory sponsor for the study. The study was 
funded by a grant to the University of Oxford from Novartis (manufacturers of 
sacubitril/valsartan). The funder had no involvement in the study conduct, analysis or the 
decision to submit for publication. All authors accept full responsibility for the content of this 
paper. The first author had full access to all the data in the study and take responsibility for its 
integrity and the data analysis. 
Clinical Trial Registration 
The trial is registered at ISRCTN11958993 (www.isrctn.com) 
 
Results 
Between 1st November 2014 and 31st January 2016, 620 participants attended screening visits 
and 566 (91%) entered the pre-randomisation run-in (Figure 1). 414 participants were 
randomized: 207 to sacubitril/valsartan and 207 to irbesartan. Mean age was 62.8 years (SD 
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13.7), 298 (72%) were male and mean blood pressure was 146/81 mmHg (Table 1). Mean eGFR 
at baseline was 35.5 (10.9) mL/min/1.73m² and median uACR was 54 (interquartile range 11-
153) mg/mmol (Table 1).  
 By 12 months, similar proportions of participants in each arm had stopped study 
treatment (33 [16%] of those assigned sacubitril/valsartan and 34 [16%] of those assigned 
irbesartan) and the reasons for stopping full dose study treatment were similar. There was no 
excess of discontinuations due to serious adverse events, non-serious adverse reactions or other 
reasons in thos allocated sacubitril/valsartan (Supplementary Table 1). 
 At 12 months, the mean (SE) mGFR was 29.8 (0.5) mL/min/1.73m² among those 
assigned sacubitril/valsartan group compared with 29.9 (0.5) mL/min/1.73m² among those 
assigned irbesartan, a non-significant difference of 0.1 (0.7) mL/min/1.73m² (P=0.86; Table 2). 
Neither a pre-specified complete case analysis (i.e. without imputation: difference -0.4 (0.7) 
mL/min/1.73m²) nor an “on treatment” analysis (difference -0.5 (0.7) mL/min/1.73m²) materially 
affected this finding. There was no evidence that the difference between sacubitril/valsartan and 
irbesartan in effect on mGFR differed by age (χ12=0.45; p=0.50), sex (χ12=0.70; p=0.4), by 
baseline mGFR (χ12=0.42; p=0.52), baseline uACR (χ12=0.76; p=0.38), cause of kidney disease 
(χ62=2.24; p=0.90) or any other pre-specified baseline characteristic (Supplementary Figure 1).  
 As compared to irbesartan, allocation to sacubitril/valsartan was not associated with any 
significant effect on eGFR at any time point (Figure 2). The rate of change in eGFR did not 
differ significantly between arms, whether measured from randomisation to 12 months, from 
randomisation to 3 months or from 3 to 12 months (Supplementary Table 2).  
 Allocation to sacubitril/valsartan produced a non-significant 9% (-18 to 1%; p=0.08) 
reduction in study-average uACR (Table 3) and was associated with a reduction in blood 
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pressure compared with irbesartan. Overall, mean systolic blood pressure was 5.4 (95% CI -7.4 
to -3.4) mmHg lower, and mean diastolic blood pressure was 2.1 (95% CI -3.3 to -1.0) mmHg 
lower among those allocated to sacubitril/valsartan (Table 3). Exploratory analyses did not show 
any differences in the intensity of non-study anti-hypertensive agents between the treatment arms 
during follow-up. 
 Allocation to sacubitril/valsartan was associated with significant reductions in levels of 
cardiac biomarkers compared with irbesartan. Study average NT-proBNP concentrations were 
18% (-25 to -11%) lower and troponin I levels were 16% (-23% to -8%) lower among 
participants assigned sacubitril/valsartan (Table 3). 
 Using data from 87 participants who had taken their last dose of sacubitril/valsartan 10-
16 hours previously, no significant determinants of sacubitril or valsartan concentration were 
identified (Supplementary Table 3). However, kidney function was a major determinant of 
sacubitrilat concentration, with each 10 mL/min lower mGFR being associated with a 1485 (572-
2397) ng/mL higher sacubitrilat concentration (Supplementary Table 3).  
 Allocation to sacubitril/valsartan had no significant effect on fatal serious adverse events 
(1 [0.5%] vs 1 [0.5%]) or on any non-fatal serious adverse events (61 [29.5%] vs 59 [28.5%]; RR 
1.07 [0.75-1.53]; p=0.70) (Supplementary Table 4). One case of angioedema occurred in a 
participant allocated sacubitril/valsartan, but they did not attend hospital or require any specific 
treatment. There was no difference overall in the number of non-serious adverse reactions (76 
[36.7%] vs 58 [28.0%]; RR 1.35 [0.96-1.90]; p=0.08) (Supplementary Table 4). Allocation to 
sacubitril/valsartan was associated with higher rates of non-serious hypotension (17 [8.2%] vs 7 
[3.4%]; RR 2.36 [1.06-5.26]; p=0.04).  There was no difference between treatments in the 
number of participants experiencing hyperkalaemia (66 [32%] vs 50 [24%]; p=0.10) or in the 
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proportion experiencing a significant decline in eGFR (defined as 25% or greater reduction; 71 
[34%] vs 67 [32%]; p=0.75) (Table 4). There were no cases of significant liver injury. 
 
Discussion 
The UK HARP-III trial has shown that, compared with irbesartan, 12 months of treatment with 
sacubitril/valsartan did not significantly affect kidney function in people with CKD. 
Sacubitril/valsartan had no additional effect on albuminuria compared to irbesartan and was as 
well-tolerated, with no major safety concerns identified. Sacubitril/valsartan was also found to 
reduce blood pressure and biomarkers of cardiovascular risk (troponin I and NT-proBNP) 
compared to irbesartan. 
 The kidney function results from UK HARP-III do not confirm findings from the 
analyses of kidney disease progression outcomes from other NEPi trials among patients with 
heart failure. In a trial among patients with heart failure with preserved ejection fraction 
(HFpEF), kidney function declined more slowly with sacubitril/valsartan compared with 
valsartan.15 In the large PARADIGM-HF trial, a marginally slower decline in eGFR was also 
observed with sacubitril/valsartan compared with enalapril (-1.3 [-1.2 to -1.4]  versus -1.8 [-1.8 
to -1.7] mL/min/1.73m2 per year; p<0.0001).16 The lack of any additional effect of 
sacubitril/valsartan on kidney function in UK HARP-III may reflect differing determinants of 
kidney disease progression in a proteinuric CKD population compared to heart failure 
populations. If cardiac function is a more important determinant of kidney function in a heart 
failure population than in proteinuric CKD, then a treatment which improves cardiac function, 
like sacubitril/valsartan, might be more likely to affect kidney function in a heart failure 
population. 
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 Studies using animal models of established kidney disease have found that combinations 
of NEP and RAS inhibition are not associated with significant differences in GFR compared with 
isolated RAS inhibition.18, 19, 21, 32 However, histology results from these animals demonstrated 
that combined NEP/RAS inhibition was associated with greater reductions in histological 
markers of CKD progression (glomerulosclerosis and tubulointerstitial fibrosis), compared with 
isolated RAS inhibition.12, 18-20 It should be noted that the largest decline in eGFR was observed 
during the first month, likely attributable to the known glomerular haemodynamic effects of RAS 
inhibition. In the remaining 11 months of observation, eGFR decline was slow in both groups, 
implying that a longer observation period may have been necessary to observe the full effect on 
kidney function. 
 Allocation to sacubitril/valsartan did not increase albuminuria, by contrast with trials 
among patients with heart failure among whom sacubitril/valsartan causes statistically significant 
(but clinically modest) increases in albuminuria (from a much lower baseline).15 If similar 
increases in albuminuria had developed in people with proteinuric CKD, this would have been of 
concern since albuminuria is associated with increased risk of progression to ESRD (although 
whether this association is directly causal remains uncertain).33-35 Nonetheless, the lack of effect 
on albuminuria despite the observed blood pressure difference raises the possibility that the 
effect on systemic blood pressure does not lead to a reduction in intraglomerular pressure. 
 Sacubitril/valsartan lowered blood pressure compared with irbesartan. Similar additional 
reductions in blood pressure compared with RAS inhibition have been shown in populations with 
heart failure or hypertension.14, 36-39 These differences were observed in the context of a median 
of one other anti-hypertensive medication being used in addition to study treatment in both 
groups. It remains uncertain whether lowering blood pressure reduces the rate of progression of 
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kidney disease,40, 41 but there is good evidence that it reduces the risk of cardiovascular events.41 
Patients with CKD are at increased risk of cardiovascular events;42 indeed, most patients with 
CKD are at higher risk of cardiovascular mortality than progression to end-stage kidney disease 
(i.e. dialysis or transplantation).9 As kidney function declines, the nature of cardiovascular 
disease changes from a typical atherosclerotic phenotype to one of structural heart disease which 
becomes increasingly prevalent such that 80% of patients starting dialysis have evidence of it.43, 
44 The finding   that NTpro-BNP (an indicator of cardiac wall stress and not a substrate of 
neprilysin) and troponin levels (a marker of cardiomyocyte necrosis) were both lower among 
participants assigned sacubitril/valsartan compared with irbesartan  has also been observed 
among patients with heart failure.39, 45, 46 Recent animal data also demonstrated that 
sacubitril/valsartan attenuates cardiac hypertrophy and fibrosis in an animal model of CKD.47 
These findings raise the hypothesis that sacubitril/valsartan may have cardiovascular benefits 
among patients with advanced CKD and provides a rationale for a clinical outcome trial.  
 Sacubitril/valsartan was generally well-tolerated and no major hazards were observed; 
although there were numerically more non-serious adverse reactions in the sacubitril/valsartan 
group this difference was not statistically significant. These randomised comparisons follow a 
placebo run-in during which 152/566 (26%) of participants withdrew, mostly for non-medical 
reasons.23 Compared to those allocated to irbesartan, there were more reports of symptoms of 
hypotension among participants allocated sacubitril/valsartan, which is expected given its larger 
blood pressure lowering effect. Because kidney function is a major determinant of sacubitrilat 
concentration, it is possible that higher concentrations of sacubitrilat in this population 
contributed to this excess in hypotension. Both treatments had similar effects on the incidence of 
hyperkalaemia and no cases of significant liver injury were observed despite high blood 
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concentrations of sacubitrilat resulting from reduced renal excretion. One participant allocated 
sacubitril/valsartan developed angioedema but did not require medical intervention and it 
resolved spontaneously.  
 Study limitations include the short duration of follow-up and the sample size which was 
not sufficiently large to test the effect of sacubitril/valsartan on clinical outcomes. The choice of 
comparator (irbesartan) might also have an effect on the interpretation of the results as it has a 
different pharmacological profile to valsartan and may provide more intense angiotensin receptor 
blockade.48 This would suggest the additional BP reduction and effects on cardiac biomarkers are 
an underestimate of the effect of neprilysin inhibition. 
 In conclusion, over 12 months in people with chronic kidney disease, the combination of 
sacubitril and valsartan is well-tolerated and has similar effects on kidney function and 
albuminuria to irbesartan, but has additional blood pressure and cardiac biomarker lowering 
effects. 
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Table 1. Baseline characteristics by randomised treatment allocation 
 
 
Sacubitril/valsartan  
(n=207) 
Irbesartan  
(n=207) 
   
Age at randomisation (years) 62.0 (14.1) 63.6 (13.4) 
<50 37 (18%) 36 (17%) 
≥50 to <70 97 (47%) 99 (48%) 
≥70 73 (35%) 72 (35%) 
Sex   
Male 148 (71%) 150 (72%) 
Female 59 (29%) 57 (28%) 
Ethnicity   
White 186 (90%) 191 (92%) 
Black 3 (1%) 4 (2%) 
South Asian 11 (5%) 7 (3%) 
Other 7 (3%) 5 (2%) 
Self-reported prior disease   
Coronary heart disease 21 (10%) 33 (16%) 
Cerebrovascular disease 16 (8%) 15 (7%) 
Peripheral vascular disease 22 (11%) 22 (11%) 
Heart failure 8 (4%) 7 (3%) 
Diabetes mellitus 81 (39%) 83 (40%) 
Systolic blood pressure at randomisation (mmHg) 146 (16) 146 (16) 
<140 76 (37%) 85 (41%) 
≥140 to <160 93 (45%) 84 (41%) 
≥160 38 (18%) 38 (18%) 
Diastolic blood pressure at randomisation (mmHg) 81 (11) 80 (11) 
<80 96 (46%) 105 (51%) 
≥80 to <90 68 (33%) 58 (28%) 
≥90 43 (21%) 44 (21%) 
Body mass index (kg/m²) 30 (6) 31 (6) 
<25 35 (17%) 33 (16%) 
≥25 to <30 74 (36%) 73 (35%) 
≥30 95 (46%) 100 (48%) 
Not available 3 1 
Medication   
Antiplatelet therapy 64 (31%) 75 (36%) 
Oral anticoagulant 13 (6%) 15 (7%) 
Diuretic 79 (38%) 85 (41%) 
Calcium channel blocker 104 (50%) 103 (50%) 
Beta blocker 50 (24%) 62 (30%) 
Alpha blocker 58 (28%) 55 (27%) 
LDL-lowering agent 126 (61%) 137 (66%) 
Use of RAS blockade at screening visit   
Yes 173 (84%) 166 (80%) 
No 34 (16%) 41 (20%) 
CKD-EPI estimated glomerular filtration rate at randomisation 
(mL/min/1.73m²)   
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Sacubitril/valsartan  
(n=207) 
Irbesartan  
(n=207) 
Mean (SD) 35.4 (11.0) 35.5 (11.0) 
<30 79 (38%) 77 (37%) 
≥30 to <45 86 (42%) 91 (44%) 
≥45 41 (20%) 39 (19%) 
Not available 1 0 
Urine albumin:creatinine ratio at randomisation (mg/mmol)   
Geometric mean (approx SE) 34 (5) 34 (5) 
Median (IQR) 52 (11-162) 56 (11-146) 
<3 30 (14%) 28 (14%) 
≥3 to <30 43 (21%) 45 (22%) 
≥30 134 (65%) 134 (65%) 
Cause of kidney disease   
Glomerular disease 60 (29%) 51 (25%) 
Tubulointerstitial disease* 18 (9%) 32 (15%) 
Diabetic kidney disease† 36 (17%) 47 (23%) 
Hypertensive/renovascular disease† 18 (9%) 24 (12%) 
Other systemic diseases affecting the kidneys† 1 (0%) 2 (1%) 
Familial/hereditary nephropathies 30 (14%) 13 (6%) 
Other known causes‡ 5 (2%) 4 (2%) 
Unknown‡ 39 (19%) 34 (16%) 
24 hour urinary sodium excretion during run-in (mg/24 hours)   
Geometric mean (approx SE) 2245 (183) 2585 (187) 
Median (IQR) 2484 (1794-3795) 2875 (1932-4232) 
Not available 100 110 
Values are n (%), mean (SD), geometric mean (approx SE) or median (IQR). RAS=Renin–angiotensin 
system. CKD-EPI=Chronic kidney disease Epidemiology Collaboration. *Includes obstructive renal 
diseases. †All considered 'Systemic diseases affecting the kidney' by the ERA-EDTA registry. ‡All 
considered 'Miscellaneous renal disorders' by the ERA-EDTA registry. 
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Table 2. Effect of allocation to sacubitril/valsartan versus irbesartan on measured glomerular filtration 
rate at 12 months 
 
Follow-up visit 
Mean mGFR (SE) (mL/min/1.73m²) Difference in means 
(SE)* p value Sacubitril/valsartan (n=207) Irbesartan (n=207) 
Randomisation 34.0 (0.8) 34.7 (0.8)   
12 months 29.8 (0.5) 29.9 (0.5) -0.1 (0.7) 0.86 
mGFR=measured glomerular filtration rate. Where the difference between mGFR and central eGFR at the 
corresponding time point was more extreme than the 1st or 99th centile of the distribution of differences, 
the value of mGFR was set to missing. 10 missing mGFR values at randomisation had eGFR values at 
randomisation imputed and 41 missing mGFR values at 12 months were imputed with the use of multiple 
imputation. For the 2 patients who commenced chronic dialysis during the study, a value of 0 was 
imputed for their 12 month mGFR. *Values are absolute differences in arithmetic means (SE). The 12 
month estimates and p values were derived from analysis of covariance with adjustment for the 
randomisation value. 
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Table 3. Effect of allocation to sacubitril/valsartan versus irbesartan on urinary albumin:creatinine ratio, systolic and diastolic blood pressure and 
cardiac biomarkers  
 
Follow-up visit 
Mean (SE)* Difference in means 
(95% CI)† p value Sacubitril/valsartan (n=207) Irbesartan (n=207) 
Urinary albumin:creatinine ratio (mg/mmol)     
Randomisation 34.1 (4.6) 33.9 (4.5)   
3 months 17.0 (1.0) 17.8 (1.0) -4% (-19 to 12%)  
6 months 15.6 (1.0) 18.4 (1.1) -15% (-28 to 0%)  
12 months 16.4 (1.2) 17.6 (1.3) -6% (-23 to 14%)  
Study average 16.3 (0.6) 17.9 (0.7) -9% (-18 to 1%) 0.08 
Systolic blood pressure (mmHg)     
Randomisation 146 (1.1) 146 (1.1)   
1 month 129 (1.1) 132 (1.1) -3.5 (-6.5 to -0.6)  
3 months 129 (1.1) 137 (1.1) -7.3 (-10.3 to -4.3)  
6 months 128 (1.1) 135 (1.1) -6.9 (-10.0 to -3.7)  
9 months 130 (1.2) 134 (1.2) -4.0 (-7.3 to -0.8)  
12 months 128 (2.5) 133 (2.2) -4.4 (-10.9 to 2.1)  
Study average 129 (0.8) 134 (0.7) -5.4 (-7.4 to -3.4) <0.001 
Diastolic blood pressure (mmHg)     
Randomisation 81 (0.8) 80 (0.8)   
1 month 73 (0.6) 74 (0.6) -0.8 (-2.5 to 0.9)  
3 months 73 (0.6) 76 (0.6) -2.6 (-4.3 to -0.9)  
6 months 72 (0.6) 75 (0.6) -2.5 (-4.2 to -0.8)  
9 months 73 (0.6) 74 (0.6) -1.8 (-3.6 to -0.1)  
12 months 72 (1.6) 75 (1.3) -2.2 (-6.2 to 1.9)  
Study average 73 (0.5) 75 (0.4) -2.1 (-3.3 to -1.0) <0.001 
N-Terminal Pro B-type Natriuretic Peptide (ng/L)     
Randomisation 254.5 (22) 250.9 (22)   
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Follow-up visit 
Mean (SE)* Difference in means 
(95% CI)† p value Sacubitril/valsartan (n=207) Irbesartan (n=207) 
6 months 175.6 (7.2) 219.7 (8.9) -20% (-29 to -11%)  
12 months 210.2 (11) 247.5 (12) -15% (-26 to -2%)  
Study average 188.7 (6.0) 230.4 (7.3) -18% (-25 to -11%) <0.001 
Troponin I (ng/L)     
Randomisation 7.3 (0.5) 7.5 (0.5)   
6 months 5.4 (0.2) 6.6 (0.2) -19% (-27 to -10%)  
12 months 6.3 (0.4) 7.1 (0.4) -11% (-24 to 4%)  
Study average 5.7 (0.2) 6.8 (0.2) -16% (-23 to -8%) <0.001 
Any missing data were imputed with the use of multiple imputation. *Geometric means (approx SE) are presented for urinary albumin:creatinine 
ratio and cardiac biomarkers, and arithmetic means (SE) are presented for blood pressure. †Values are percentage changes in geometric means 
(95% CI) for urinary albumin:creatinine ratio and cardiac biomarkers, and absolute differences in arithmetic means (95% CI) for blood pressure. 
The estimates and p values at each follow-up visit were derived from analysis of covariance with adjustment for the randomisation value. 
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Table 4. Effect of allocation to sacubitril/valsartan versus irbesartan on biochemical safety data 
 
Outcome 
Sacubitril/valsartan 
(n=207) 
Irbesartan 
(n=207) p-value 
Potassium (mmol/L)    
≥5.5 to <6.0 44 (21%) 38 (18%)  
≥6.0 to <6.5 20 (10%) 7 (3%)  
≥6.5 2 (1%) 5 (2%)  
Total: Any potassium ≥5.5 mmol/L 66 (32%) 50 (24%) 0.10 
Estimated glomerular filtration rate    
≥25% reduction in CKD-EPI eGFR* 71 (34%) 67 (32%) 0.75 
CKD-EPI=Chronic kidney disease Epidemiology Collaboration. eGFR=estimated glomerular filtration 
rate. Based on local laboratory measurements. *compared to eGFR at randomisation visit. 
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Figure Legends 
 
Figure 1. Flow of participants 
* Participants could report more than one reason 
† The duration of the trial was increased from 6 to 12 months and 9 participants did not consent 
to this extension so completed follow-up at 6 months. 
 
Figure 2. Effect of allocation to sacubitril/valsartan versus irbesartan on estimated 
glomerular filtration rate  
Creatinine measured in central laboratory except for 1 and 9 month visits when creatinine was 
measured in local laboratory. Error bars presented are 95% confidence intervals. 


